Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 78 resultados
LastUpdate Última actualización 15/05/2025 [06:45:00]
pdfxls
Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days
previousPage Resultados 75 a 78 de 78  

PROTEASOME INHIBITORS AND METHODS OF USE THEREOF

NºPublicación:  WO2025080942A1 17/04/2025
Solicitante: 
THE BRIGHAM AND WOMEN\u2019S HOSPITAL INC [US]
PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US]
THE BRIGHAM AND WOMEN\u2019S HOSPITAL, INC,
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
WO_2025080942_A1

Resumen de: WO2025080942A1

The present disclosure provides proteasome inhibitors of Formula (I), useful in treating cancer, such as multiple myeloma and mantle cell lymphoma.

ANTI-BCMA SINGLE-DOMAIN ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF

NºPublicación:  WO2025077315A1 17/04/2025
Solicitante: 
CARBIOGENE THERAPEUTICS CO LTD [CN]
\u6D59\u6C5F\u5EB7\u4F70\u88D5\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8
WO_2025077315_A1

Resumen de: WO2025077315A1

Provided are an anti-BCMA single-domain antibody, and a preparation method therefor and the use thereof. Specifically, provided is a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can thoroughly specifically target BCMA-positive cells, and can be applied to the detection of BCMA expression in bone marrow cells of MM patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating BCMA-target-related diseases (such as multiple myeloma, B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma and Hodgkin's lymphoma); or a BCMA protein detection kit, etc. The single-domain antibody has a stable structure, a small molecular size, is easily recombinantly expressed and has a low production cost, can be used alone or as a drug delivery system to carry relevant drugs, and has very wide prospects and important significance in fields such as drug application and clinical diagnosis.

MULTI-SPECIFIC ANTIBODY TARGETING BCMA, GPRC5D AND T CELLS AND APPLICATION THEREOF

Nº publicación: EP4538294A1 16/04/2025

Solicitante:

SHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD [CN]
Shandong Simcere Biopharmaceutical Co., Ltd

EP_4538294_A1

Resumen de: EP4538294A1

The present application relates to a multi-specific binding molecule targeting BCMA, GPRC5D and a T cell receptor. In particular, the present application discloses a multi-specific antibody against BCMA, GPRC5D and CD3, which can bind to a tumor surface antigen while activating T cells, thereby promoting the specific killing of tumor cells, in particular BCMA-positive or GPRC5D-positive multiple myeloma, by T cells. The present application further provides a preparation method for and the application of the multi-specific binding molecule.

traducir